Seo Salimi is a partner in Goodwin's Technology Companies & Life Sciences Group. His practice focuses on corporate transactions and securities laws with a particular emphasis on representing clients in public and private capital markets transactions such as initial public offerings, follow-on offerings and private placements of equity and debt securities. His clients include global investment banks, issuers and venture capital investors. His experience extends to a variety of industries, with a focus on life sciences.




Mr. Salimi also routinely counsels clients on corporate governance matters, federal and state securities law issues and rules and interpretations of the Financial Industry Regulatory Authority and various trading markets, including the NYSE and NASDAQ. A selection of Mr. Salimi’s recent representations include:

Domestic Representations 

  • JP Morgan and Goldman Sachs as underwriters in a $300 million follow-on offering by Sarepta Therapeutics, Inc.
  • Morgan Stanley and Credit Suisse as underwriter in $125 million follow-on offering of Sarepta Therapeutics
  • Citigroup as underwriter in the $60 million initial public offering of Reata Pharmaceuticals Inc.
  • Cowen and Company in “At-the-Market” transactions for various life science companies
  • Cowen and Company, as underwriter in a $143.8 million public offering of Dynavax Technologies
  • Credit Suisse and Bank of America  in the $90 million initial public offering by Everbridge, Inc. 
  • Repligen Corporation in $115 million senior convertible notes offering
  • General company representation of Repligen Corp

Cross-Border Representations

  • CRISPR Therapeutics AG in its $62 million initial public offering (Country of Issuer: Switzerland)
  • General company representation of CRISPR Therapeutics AG    
  • Citigroup and Morgan Stanley, as underwriters in a $280 million follow-on offering of American Depositary Shares by DBV Technologies (Country of Issuer: France)
  • Citigroup as underwriter in the $70 million initial public offering of AC Immune SA (Country of Issuer: Switzerland)
  • H.C. Wainwright in a public offering by Aurinia Pharmaceuticals Inc. (Country of Issuer: Canada)
Professional Activities

Mr. Salimi is a member of the California and New York bar associations.


Prior to joining Goodwin, Mr. Salimi was an associate at Latham & Watkins LLP and Hogan Lovells LLP. Mr. Salimi also served as the General Counsel of a NASDAQ listed company.

In The News







J.D., 2004
University of Southern California, Gould School of Law
B.A., 2001
University of California, Irvine



New York
Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers